Sangamo files Chapter 11, agrees to sell assets to Lilly, Astellas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
June 23, 2026 8:05 AM EDTSangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders
Lilly and Astellas to serve as stalking horse bidders in a court-supervised auction process
Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations
RICHMOND, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that it has entered into two separate asset sale agreements, one with Eli... More
